hrp0097p1-347 | Pituitary, Neuroendocrinology and Puberty | ESPE2023
Mohamed Duaa
, Al Remeithi Sareea
, Al Jneibi Sara
, Elyazori Yara
Background: GnRHa is the treatment for CPP, it arrests puberty progression, slows bone age (BA) maturation, and increases pubertal height. In the last decades, the use of GnRHa has demonstrated its favorable effects on linear growth, although the net height gain and predictors of long-term outcomes remains debated. Concerns raised on thepotential negative effects of treatment on weight and reproductive function.Methods: ...